Envista Holdings Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US29415F1049
USD
20.13
-0.32 (-1.56%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Envista Holdings Corp. stock-summary
stock-summary
Envista Holdings Corp.
Pharmaceuticals & Biotechnology
Envista Holdings Corporation is a dental products company. The Company provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone. The Company operates through two segments: Specialty Products & Technologies, and Equipment & Consumables. Its Specialty Products & Technologies segment develops, manufactures and markets dental implant systems, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. Its Equipment & Consumables segment develops, manufactures and markets dental equipment and supplies used in dental offices, including digital imaging systems, software and other visualization/magnification systems; treatment units and other dental practice equipment; endodontic systems and related consumables; restorative materials and instruments, rotary burs, impression materials, bonding agents and cements and infection prevention products.
Company Coordinates stock-summary
Company Details
200 S Kraemer Blvd Bldg E , BREA CA : 92821-6208
stock-summary
Tel: 1 714 51677741 714 8177000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 105 Schemes (75.46%)

Foreign Institutions

Held by 177 Foreign Institutions (17.32%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Scott Huennekens
Independent Chairman of the Board
Mr. Amir Aghdaei
President, Chief Executive Officer, Director
Mr. Daniel Raskas
Director
Ms. Wendy Carruthers
Independent Director
Mr. Kieran Gallahue
Independent Director
Mr. Vivek Jain
Independent Director
Ms. Gayle Sheppard
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
682 Million
(Quarterly Results - Jun 2025)
Net Profit:
26 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,515 Million (Small Cap)

stock-summary
P/E

73.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.12

stock-summary
Return on Equity

2.07%

stock-summary
Price to Book

1.12